Literature DB >> 25591779

Olopatadine inhibits exocytosis in rat peritoneal mast cells by counteracting membrane surface deformation.

Asuka Baba1, Masahiro Tachi, Yoshio Maruyama, Itsuro Kazama.   

Abstract

BACKGROUND/AIMS: Besides its anti-allergic properties as a histamine receptor antagonist, olopatadine stabilizes mast cells by inhibiting the release of chemokines. Since olopatadine bears amphiphilic features and is preferentially partitioned into the lipid bilayers of the plasma membrane, it would induce some morphological changes in mast cells and thus affect the process of exocytosis.
METHODS: Employing the standard patch-clamp whole-cell recording technique, we examined the effects of olopatadine and other anti-allergic drugs on the membrane capacitance (Cm) in rat peritoneal mast cells during exocytosis. Using confocal imaging of a water-soluble fluorescent dye, lucifer yellow, we also examined their effects on the deformation of the plasma membrane.
RESULTS: Low concentrations of olopatadine (1 or 10 µM) did not significantly affect the GTP-γ-S-induced increase in the Cm. However, 100 µM and 1 mM olopatadine almost totally suppressed the increase in the Cm. Additionally, these doses completely washed out the trapping of the dye on the cell surface, indicating that olopatadine counteracted the membrane surface deformation induced by exocytosis. As shown by electron microscopy, olopatadine generated inward membrane bending in mast cells.
CONCLUSION: This study provides electrophysiological evidence for the first time that olopatadine dose-dependently inhibits the process of exocytosis in rat peritoneal mast cells. Such mast cell stabilizing properties of olopatadine may be attributed to its counteracting effects on the plasma membrane deformation in degranulating mast cells.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25591779     DOI: 10.1159/000369704

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

1.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

Review 2.  Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary sequelae after COVID-19 Infection.

Authors:  Valentina Ruggiero; Rita P Aquino; Pasquale Del Gaudio; Pietro Campiglia; Paola Russo
Journal:  Pharmaceutics       Date:  2022-05-26       Impact factor: 6.525

3.  Second-Generation Histamine H1 Receptor Antagonists Suppress Delayed Rectifier K+-Channel Currents in Murine Thymocytes.

Authors:  Kazutomo Saito; Nozomu Abe; Hiroaki Toyama; Yutaka Ejima; Masanori Yamauchi; Hajime Mushiake; Itsuro Kazama
Journal:  Biomed Res Int       Date:  2019-04-30       Impact factor: 3.411

4.  Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis.

Authors:  Itsuro Kazama
Journal:  Clin Mol Allergy       Date:  2021-12-13

5.  Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies.

Authors:  Edward Meier; Abhijit Narvekar; Ganesh R Iyer; Harvey B DuBiner; Apinya Vutikullird; David Wirta; Kenneth Sall
Journal:  Clin Ophthalmol       Date:  2017-04-10

6.  α 1-Adrenergic Receptor Blockade by Prazosin Synergistically Stabilizes Rat Peritoneal Mast Cells.

Authors:  Nozomu Abe; Hiroaki Toyama; Yutaka Ejima; Kazutomo Saito; Tsutomu Tamada; Masanori Yamauchi; Itsuro Kazama
Journal:  Biomed Res Int       Date:  2020-05-12       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.